MRI Interventions Announces Agreement with Siemens Healthineers For Interfacing with the Portfolio of Magnetom MRI Scanners
Agreement Enables the Development of More Efficient Clinical Workflows, Advanced Functionality and Shorter Surgical Procedure Times In the MRI Suite
IRVINE, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a platform neurosurgery company developing products designed for navigation, ablation, deep brain stimulation, biopsy, aspiration and gene therapy, today announced a collaborative agreement with Siemens Healthineers for the integration of the ‘Access-I’ software solution available on the Magnetom family of scanners worldwide with MRI Interventions’ ClearPoint® Neuro Navigation System. This advanced level of access and compatibility will facilitate faster pre-planning and peri-procedural data transfer to and from the ClearPoint System for use in both navigation and therapy procedures.
“As the movement toward minimally invasive neurosurgery continues, we have the opportunity to be leaders in defining the workflows that will be utilized in the future,” commented Joe Burnett, President and CEO of MRI Interventions. “Our development of the ClearPoint Neuro Navigation System has enhanced precision in neurosurgery over the past decade, in such applications as deep-brain stimulation lead placement, laser ablation, biopsy and gene therapy. We now need to achieve the next level of maturity in this space and make the procedures faster, more predictable and more repeatable, which inevitably yields higher quality and lower costs. We believe a close and comprehensive integration is necessary with our scanner partners to accomplish this, and we now have such a partnership with Siemens to define this important next step.”
Access-I is a commercial software from Siemens Healthineers that is fully compatible with Siemens’ Magnetom Scanner portfolio and allows third-party device integration through interactive remote control and data access procedures and protocols.
About MRI Interventions, Inc.
MRI Interventions is a leading platform company for MRI-guided neurosurgery procedures, including deep-brain stimulation, ablation, aspiration, biopsy, and gene therapy delivery. The ClearPoint Neuro Navigation System is FDA cleared and CE marked, and is installed in more than 55 surgical centers in the U.S. To date, nearly 3,000 procedures have been performed leveraging the sub-millimetric accuracy of the ClearPoint platform. For more information, please visit www.mriinterventions.com.
Statements herein concerning MRI Interventions, Inc.’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company’s ability to obtain additional financing; estimates regarding the sufficiency of the Company’s cash resources; future revenues from sales of the company’s ClearPoint Neuro Navigation System products; and the company’s ability to market, commercialize and achieve broader market acceptance for the company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the company’s actual results are described in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year ended December 31, 2017, and its Quarterly Report on Form 10-Q for the three months ended September 30, 2018, both of which have been filed with the Securities and Exchange Commission, and the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, which the Company intends to file with the Securities and Exchange Commission on or before April 1, 2019.
Matt Kreps, Darrow Associates Investor Relations